The new indication of "everolimus" was approved, and breast cancer treatment ushered in a new era of "endocrine +"

Good news for breast cancer patients: Novartis Afinitor® ⁽ everolimus tablet) was recently approved by the State Drug Administration for a new indication, in combination with exemestane for the treatment of letrozole or anastrozole Hormone receptor-positive, epidermal growth factor receptor-2-negative, postmenopausal women with advanced breast cancer after failure
.
Previously, Afinitor® ⁽ everolimus tablets) has been approved for the treatment of advanced renal cell carcinoma, tuberous sclerosis-related renal angiomyolipoma, neuroendocrine tumors,

etc.

Good news for breast cancer patients: Novartis Afinitor ^{® (} everolimus tablet) was recently approved by the State Drug Administration for a new indication, in combination with exemestane for the treatment of letrozole or anastrozole Hormone receptor-positive, epidermal growth factor receptor-2-negative, postmenopausal women with advanced breast cancer after treatment failure

Ms.

Everolimus Provides New "Endocrine+" Choice for Advanced Breast Cancer Patients Everolimus Provides "Endocrine+" New Choice for Advanced Breast Cancer Patients

According to the survey report of the International Agency for Research on Cancer of the World Health Organization, in 2020, there will be 420,000 new cases of breast cancer in Chinese women, ranking first in the number of new cancer cases among Chinese women

.

According to the survey report of the International Agency for Research on Cancer of the World Health Organization, in 2020, there will be 420,000 new cases of breast cancer in Chinese women, ranking first in the number of new cancer cases among Chinese women

For HR+/HER2- advanced breast cancer, major guidelines recommend endocrine therapy as the first choice

Novartis Afinitor ^{® ®} (everolimus tablet), which is newly added for this indication, is an oral selective mTOR inhibitor that binds to the intracellular protein FKBP12, thereby inhibiting the activity of mTOR

The treatment effect of everolimus combined with exemestane is remarkable, and it is recommended by domestic and foreign guidelines.
Everolimus combined with exemestane has significant therapeutic effect and is recommended by domestic and foreign guidelines

mTOR inhibitors have been used in cancer therapy for many years
.
In the field of breast cancer, the combined application of everolimus and exemestane in the treatment of hormone receptor-positive, HER2-negative advanced breast cancer has been recommended by NCCN and other international guidelines, and is listed in the "Guidelines and Specifications for Breast Cancer Diagnosis and Treatment of the Chinese Anti-Cancer Association" ( In the 2021 edition of CBCS), everolimus was recommended as a commonly used regimen related to endocrine therapy

.

mTOR inhibitors have been used in cancer therapy for many years

The approval of this indication is based on the BOLERO-5 study conducted in China, which is an evaluation of everolimus combined with exemestane in the treatment of HR+/HER2- relapsed after prior letrozole or anastrozole therapy.

"I am very pleased to see that everolimus has been approved in China for the indication of breast cancer, which allows our clinicians to add a new treatment method
.

As a representative of mTOR inhibitors, Afinitor ^{® (} everolimus) has been approved for marketing in more than 120 countries including the United States, Europe and Japan, and has accumulated more than 70,000 evidence-based use cases worldwide .

References

1 , Jia M, Liao N, et al.
Breast Cancer.
2021 May;28(3):644-652.

1 , Jia M, Liao N, et al.

Breast Cancer.
2021 May;28(3):644-652.

2.
Shao Zhimin , Abstract # 238P, 2021 ESMO

2.
Shao Zhimin , Abstract # 238P, 2021 ESMO leave a message here